

The information in the press release is intended for investors.

Isofol invites to investor meeting on November 20, 2024

GOTHENBURG, Sweden, October 25, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites investors and shareholders to an investor meeting to present the latest about the company and the drug candidate arfolitixorin.

Isofol invites to an investor meeting to present the company's evidence platform, study design and strategy going forward. The meeting will be held in Gothenburg but can also be followed online. The presentation is mainly held in Swedish and an English version will be available on the website after the event. Participants will have the opportunity to ask questions, both on site and online.

Date and time

Wednesday November 20, at 17.30-18.30 (webcast)

Venue

Arvid Wallgrens Backe 20, 5th floor, Gothenburg and webcast

Agenda

17.00–17.30 Registration

17.30–18.30 Isofol's evidence platform and basis for clinical studies

Clinical study design

Market outlook and Isofol's strategy

Q&A

18.30-19.30 Mingle and refreshments

Registration

You are welcome to register via the company's website, no later than November 12:

<https://isofolmedical.com/investor-meeting-november-20-2024/>

Please note that the number of seats is limited at the venue. When the registration period has expired you will receive a confirmation by e-mail with a web link included if you want to follow the investor meeting online. This link will be published on Isofol's website after November 12.

An English presentation will also be available on Isofol's website afterward.

For more information, please contact

Isofol Medical AB (publ)

Petter Segelman Lindqvist, CEO

E-mail: petter.s.lindqvist@isofolmedical.com

Telephone: +46 (0)739 60 12 56

The information was submitted for publication, through the agency of the contact person set out above, at 10:45 CEST, on October 25, 2024.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company's drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin's efficacy. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofofmedical.com